196,275 research outputs found
Extended middle east and North Africa: Cervical cancer and human papillomavirus: Can we make the case for prevention in this Relatively Low Prevalence Region?
No full text[No abstract available]Bouvard V, 2009, LANCET ONCOL, V10, P321; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086-657321; Burchell AN, 2006, VACCINE S3, V24, pS52, DOI DOI 10.1016-J.VACEINE.2006.05.031; Corinne R., IRAQS ONCE ENVIED HL; DeJong J, 2005, REPROD HEALTH MATTER, V13, P49, DOI 10.1016-S0968-8080(05)25181-9; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016-j.virol.2004.03.033; Dominique Tabutin, 2005, POPULATION E, V60, P505, DOI 10.2307-4148186; Ferlay J, 2010, IARC CANC BASE; Finer LB, 2007, PUBLIC HEALTH REP, V122, P73; FRIEDMAN HL, 1992, J ADOLESCENT HEALTH, V13, P345, DOI 10.1016-1054-139X(92)90026-8; Jumaan AO, 2013, VACCINE, V31, pG58, DOI 10.1016-j.vaccine.2012.06.097; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056-NEJMoa021641; Sancho-Garnier H, 2013, VACCINE, V31, pG51, DOI 10.1016-j.vaccine.2012.06.046; Seoud M., 2012, J LOW GENIT TRACT DI, V16, P102; Trottier H, 2006, VACCINE, V24, pS1, DOI DOI 10.1016-J.VACEINE.2005.09.054; United States Census Bureau, WORLD POP 1950 2050; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002-(SICI)1096-9896(199909)189:112::AID-PATH4313.0.CO;2-F; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111-j.1931-2393.2004.tb00002.x; WHO-ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), HUM PAP REL CANC WOR; World Health Organization, AIDS SEX TRANSM DIS; World Health Organization, AIDS EP UPD0
Burden of human papillomavirus-related cervical disease in the extended Middle East and North Africa - A comprehensive literature review
No full textOBJECTIVE: This study aimed to analyze the burden of human papillomavirus (HPV) in the Extended Middle East and North Africa (EMENA) region and to discuss the potential impact on HPV-related diseases derived from changing sexual behaviors and perceptions. MATERIALS AND METHODS: A comprehensive retrospective review of the available epidemiological data (publications in the past 30 years until January 2011) on HPV and its related diseases (especially as they relate to the cervix) in the EMENA region was carried out. RESULTS: Analysis of the burden of HPV in the EMENA region highlights an unexpectedly high prevalence of HPV, with rates of HPV ranging from 0percent to 25percent in low-risk women with normal cytology and up to 98percent in those with genital warts and preinvasive and invasive lesions. In addition, cervical cancer screening practices are, at best, opportunistic in most countries of the region; therefore, the observed change in social and sexual behavior in the EMENA population, particularly in youths, could lead to an increase in HPV and its related diseases especially cervical cancer. CONCLUSIONS: This article emphasizes the need for the introduction and standardization of screening practices in the region. Moreover, surveillance studies are needed to enable the identification of HPV type distribution and to determine the potential impact of the introduction of HPV vaccines. These socio-epidemiological data are of marked value to health care decision and policymakers in prioritizing available public health interventions. © 2012 The American Society for Colposcopy and Cervical Pathology.Abdel Aziz MT, 2006, MED SCI MONITOR, V12, pMT43; Agacfidan A, 2001, SEX TRANSM DIS, V28, P630, DOI 10.1097-00007435-200111000-00004; Ahmed MI, 2001, CLIN BIOCHEM, V34, P491, DOI 10.1016-S0009-9120(01)00243-0; Alami K, 2002, East Mediterr Health J, V8, P794; Al-Awadhi R, 2011, J MED VIROL, V83, P453, DOI 10.1002-jmv.21981; Ali F, 1996, J Egypt Public Health Assoc, V71, P553; Al-Muammar T, 2007, ANN SAUDI MED, V27, P1, DOI 10.4103-0256-4947.51540; Al-Mutairi N, 2007, INT J DERMATOL, V46, P594, DOI 10.1111-j.1365-4632.2007.02843.x; Amrani M, 2003, J CLIN VIROL, V27, P286, DOI 10.1016-S1386-6532(02)00227-5; [Anonymous], SEX TRANSM DIS SURV; [Anonymous], 2013, TELEGRAPH; [Anonymous], 1994, STUD FAM PLANN, V25, P191; ANWAR K, 1991, INT J CANCER, V47, P675, DOI 10.1002-ijc.2910470508; Aras S, 2007, J BIOSOC SCI, V39, P121, DOI 10.1017-S0021932006001258; Aras S, 2007, J SCH HLTH, V77, P79; Aras S, 2007, J SCHOOL HEALTH, V77, P359, DOI 10.1111-j.1746-1561.2007.00220.x; Assaad R, YOUTH MIDDLE E N AFR; Awwad Ziad M., 2003, International Journal of Infectious Diseases, V7, P206, DOI 10.1016-S1201-9712(03)90053-1; Aydin Faruk, 2002, Mikrobiyoloji Bulteni, V36, P85; Aydin Y, 2010, EUR J GYNAECOL ONCOL, V31, P72; Badrinath P., 2004, BMC WOMENS HEALTH, V4, P3, DOI 10.1186-1472-6874-4-3; Bamberger ES, 2003, EMERG INFECT DIS, V9, P1344; BARAM A, 1995, ISRAEL J MED SCI, V31, P349; Bashawri LA, 2002, SAUDI MED J, V23, P555; Ben Hamida A, 1999, REV EPIDEMIOL SANTE, V47, P397; Biri A, 2007, MATURITAS, V58, P236, DOI 10.1016-j.maturitas.2007.08.010; BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093-jnci-87.11.796; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016-j.vaccine.2008.05.064; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086-657321; Burchell AN, 2006, VACCINE S3, V24, pS52, DOI DOI 10.1016-J.VACEINE.2006.05.031; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002-(SICI)1097-0215(19980209)75:4546::AID-IJC93.0.CO;2-T; Cirpan T, 2007, EUR J GYNAECOL ONCOL, V28, P302; Cobb JC, 1997, AM J PUBLIC HEALTH, V87, P1380, DOI 10.2105-AJPH.87.8.1380; Crochard A, 2009, GYNECOL ONCOL, V115, pS7, DOI 10.1016-j.ygyno.2009.06.003; Cwikel Julie G, 2006, Sex Health, V3, P301, DOI 10.1071-SH06048; De Marco F, 2006, J MED VIROL, V78, P950, DOI 10.1002-jmv.20646; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016-S1470-2045(10)70230-8; Dolapci I, 2005, SAUDI MED J, V26, P64; Dominique Tabutin, 2005, POPULATION E, V60, P505, DOI 10.2307-4148186; Dursun P, 2009, BMC INFECT DIS, V9, DOI 10.1186-1471-2334-9-191; el-All Howayda S Abd, 2007, Infect Agent Cancer, V2, P12; Ergunay K, 2007, MIKROBIYOL BUL, V41, P219; Faisel A, 2006, SEX TRANSM INFECT, V82, P307, DOI 10.1136-sti.2005.018762; Farjadian S, 2003, PATHOL ONCOL RES, V9, P121; Finan RR, 2006, CLIN MICROBIOL INFEC, V12, P927, DOI 10.1111-j.1469-0691.2006.01479.x; Finer LB, 2007, PUBLIC HEALTH REP, V122, P73; FRIEDMAN HL, 1992, J ADOLESCENT HEALTH, V13, P345, DOI 10.1016-1054-139X(92)90026-8; Gazzaz FSB, 2007, SAUDI MED J, V28, P1810; Gdoura R, 2001, EUR J CONTRACEP REPR, V6, P102, DOI 10.1080-713604209; Gdoura R, 2008, J ANDROL, V29, P198, DOI 10.2164-jandrol.107.003566; Ghaffari Saeed Reza, 2006, Asian Pac J Cancer Prev, V7, P529; Ghanaat Javad, 2003, Med Sci Monit, V9, pCR91; Ghazal-Aswad S, 2006, J OBSTET GYNAECOL RE, V32, P63, DOI 10.1111-j.1447-0756.2006.00352.x; Grisaru D, 2008, J CLIN MICROBIOL, V46, P1602, DOI 10.1128-JCM.02483-07; Guney AI, 1997, EUR J GYNAECOL ONCOL, V18, P546; Hajjaj AA, 2006, SAUDI MED J, V27, P487; Hamkar R, 2002, East Mediterr Health J, V8, P805; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002-ijc.20600; Hashemi FB, 2007, INFECT DIS OBSTET GY; Hassen E, 1999, Tunis Med, V77, P497; Hassen E, 2003, INFECTION, V31, P143, DOI 10.1007-s15010-003-3112-7; Heikel J, 1999, EUR J EPIDEMIOL, V15, P711, DOI 10.1023-A:1007639928462; Inal MM, 2007, INT J GYNECOL CANCER, V17, P1266, DOI 10.1111-j.1525-1438.2007.00944.x; ISACSOHN M, 1994, ISRAEL J MED SCI, V30, P383; Joffe H, 2006, ISRAEL MED ASSOC J, V8, P333; Kafi SK, 2000, UPSALA J MED SCI, V105, P249; Khair M Meftah El, 2009, J Med Virol, V81, P678, DOI 10.1002-jmv.21279; Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016-j.ijid.2006.06.007; Khanani Rafiq, 1994, JPMA (Journal of the Pakistan Medical Association), V44, P70; Kharfi M, 2000, Tunis Med, V78, P508; Kocak N, 2004, J INT MED RES, V32, P671; Lalaoui K, 2003, CLIN MICROBIOL INFEC, V9, P144, DOI 10.1046-j.1469-0691.2003.00494.x; Lubbad A M, 2007, West Afr J Med, V26, P138; Maleknejad Parviz, 2006, Daru, V14, P78; Massoud M, 1991, J Egypt Public Health Assoc, V66, P411; Mawajdeh Salah M, 2003, Health Care Women Int, V24, P635, DOI 10.1080-07399330390217734; Menczer J, 2000, EUR J GYNAECOL ONCOL, V21, P30; MITRANIROSENBAUM S, 1988, EUR J CANCER CLIN ON, V24, P725, DOI 10.1016-0277-5379(88)90306-9; Mortazavi S, 2002, ASIAN PAC J CANCER P, V3, P69; Mostafa S R, 1999, East Mediterr Health J, V5, P740; Mroueh AM, 2002, EUR J GYNAECOL ONCOL, V23, P429; Murillo R., 2009, INFECT DIS OBSTET GY, V2009; Mutlu Birsen, 2004, Mikrobiyoloji Bulteni, V38, P445; Nabi Souad, 2006, Tunis Med, V84, P170; OMER EFE, 1982, TROP DOCT, V12, P208; Onan MA, 2005, EUR J GYNAECOL ONCOL, V26, P632; Ortayli N, 2001, SEX TRANSM DIS, V28, P58, DOI 10.1097-00007435-200101000-00013; Ozcelik B, 2003, EUR J GYNAECOL ONCOL, V24, P157; Ozdag D, 2007, MIKROBIYOL BUL, V41, P51; Ozturk CE, 2006, SAUDI MED J, V27, P1503; Ozturk Sual, 2004, Mikrobiyoloji Bulteni, V38, P223; Planned Parenthood Federation of America Inc., OUT; Radouani F, 1997, PATHOL BIOL, V45, P491; Raza SA, 2010, BRIT J CANCER, V102, P1657, DOI 10.1038-sj.bjc.6605664; Rehan N, 2006, J Pak Med Assoc, V56, pS60; Safaei A, 2010, INDIAN J PATHOL MICR, V53, P681, DOI 10.4103-0377-4929.72030; Sami Shehla, 2005, JPMA Journal of the Pakistan Medical Association, V55, P242; Saxena AK, 2002, SCAND J INFECT DIS, V34, P88, DOI 10.1080-00365540110077353; Sellami Amina, 2003, Tunis Med, V81, P162; Sellors JW, 2000, CAN MED ASSOC J, V163, P503; Seoud M, 2010, GYNECOL ONCOL, V116, pS39; Sirmatel F, 2005, JPN J INFECT DIS, V58, P41; Smith JS, 2008, J ADOLESCENT HEALTH, V43, p[S5, S25, e1]; Srugo I, 2003, ISRAEL MED ASSOC J, V5, P24; Sughayer MA, 2010, INT J GYNECOL OBSTET, V108, P74, DOI 10.1016-j.ijgo.2009.08.025; Sullam S A, 2001, East Mediterr Health J, V7, P139; Sultan F, 2007, INT J INFECT DIS, V11, P407, DOI 10.1016-j.ijid.2006.10.004; TAHA OMA, 1979, BRIT J VENER DIS, V55, P313; Tamim H, 2002, DIAGN MICR INFEC DIS, V43, P277, DOI 10.1016-S0732-8893(02)00403-0; Trottier Helen, 2006, Vaccine, V24 Suppl 1, pS1; Unicef World Health Organization, IMM SUMM; United Nations, 2008, WORLD MARR DAT 2008; US Department of State, SAUD AR COUNTR SPEC; Usubutun A, 2009, INT J GYNECOL PATHOL, V28, P541, DOI 10.1097-PGP.0b013e3181aaba0d; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111-j.1931-2393.2004.tb00002.x; Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016-S0140-6736(06)69479-8; WHO, 2010, HUM PAP REL CANC SUM; World Health Organization, WHO ICO INF CTR HUM; World Health Organization, AIDS SEX TRANSM DIS; Zirak-Zadah T, 1977, Trop Doct, V7, P57; Znazen Abir, 2003, Tunis Med, V81, P32969
Supplemental Material - A Test of Minority Stress Theory with Asian Americans
No full textSupplemental Material for A Test of Minority Stress Theory with Asian Americans by Nina Lei, Brandon L. Velez, Judy M. Seoud, and Wei N. Motulsky in The Counseling Psychologist</p
Cervical adenocarcinoma: Moving towards better prevention
No full textObjective: Although cervical screening has led to a significant decline of invasive cervical cancer (ICC) in developed countries, it remains the third leading cause of cancer in women worldwide. While the majority of the decline in ICC can be attributed to a reduction in squamous cell carcinoma (SCC), the incidence of cervical adenocarcinoma (ADC), absolute and relative to SCC, has been rising steadily, especially in younger women. This paper examines oncogenic human papillomavirus (HPV) infections, the risk of developing cervical ADC and its prognosis. It analyzes differences between ADC and SCC and considers current and future methods for prevention. Methods: PubMed, publicly available websites and congress abstracts were searched for data and literature. Results: HPV-16, -18 and -45 account for approximately 90percent of ADC worldwide. Typically, α-7 genotypes, which include HPV-18 and -45, are more commonly associated with ADC than SCC. The difficulty in detecting ADC through screening as well as changing sexual habits and increased HPV transmission may account for its increase; an increase in SCC may not be observed because of improved detection of pre-malignant SCC compared with pre-malignant ADC. HPV testing shows promise for screening women ≥30. years of age, but α-7 genotypes may be underrepresented in precancerous lesions. Clinical trial data indicate that current vaccines have high efficacy against HPV-16-18-related cervical intraepithelial neoplasia. Moreover, these vaccines also demonstrate a different level of protection beyond the HPV vaccine types, therefore increasing the overall vaccine efficacy. Such broad coverage could translate into a considerable reduction in the incidence of ADC. Conclusion: Prophylactic HPV vaccination may have a significant impact on the prevention of ADC and may significantly impact future strategies for primary and secondary prevention of cervical cancer. © 2011 Elsevier Ltd.Advisory Committee on Cancer Prevention, 2000, EUR J CANCER, V36, P1473; Altekruse SF, 2003, AM J OBSTET GYNECOL, V188, P657, DOI 10.1067-mob.2003.132; *AM CANC SOC, 2009, WHAT IS CERV CANC; American College of Obstetricians and Gynecologists, 2009, OBSTET GYNECOL, V114, P1409; ANDERSON GH, 1992, OBSTET GYNECOL, V80, P1; [Anonymous], 2002, CERV CANC SCREEN DEV; ANTONCULVER H, 1992, AM J OBSTET GYNECOL, V166, P1507; Anttila A, 2009, EUR J CANCER, V45, P2685, DOI 10.1016-j.ejca.2009.07.017; Anttila A, 2009, EUR J CANCER, V45, P2649, DOI 10.1016-j.ejca.2009.07.020; Anttila A, 2010, BRIT MED J, V340, DOI 10.1136-bmj.c1804; Anttila A, 2004, BRIT J CANCER, V91, P935, DOI 10.1038-sj.bjc.6602069; Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097-01.AOG.0000296488.85807.b3; Arbyn M, 2008, EUROPEAN GUIDELINES; Arbyn M, 2007, CYTOPATHOLOGY, V18, P133, DOI 10.1111-j.1365-2303.2007.00464.x; Arbyn M, 2010, ANN ONCOL, V21, P448, DOI 10.1093-annonc-mdp471; Arbyn M, 2008, BRIT MED J, V337, DOI 10.1136-bmj.a1284; Ashfaq R, 1999, ACTA CYTOL, V43, P81; Baalbergen A, 2004, GYNECOL ONCOL, V92, P262, DOI 10.1016-j.ygyno.2003.09.001; Badaracco G, 2002, J MED VIROL, V67, P574, DOI 10.1002-jmv.10141; Badaracco G, 2005, INT J ONCOL, V27, P161; Bai HW, 2000, DIAGN CYTOPATHOL, V23, P19, DOI 10.1002-1097-0339(200007)23:119::AID-DC43.0.CO;2-K; BEREK JS, 1985, OBSTET GYNECOL, V65, P46; BERTRAND M, 1987, AM J OBSTET GYNECOL, V157, P21; BOON ME, 1981, CANCER, V48, P768, DOI 10.1002-1097-0142(19810801)48:3768::AID-CNCR28204803183.0.CO;2-L; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016-j.vaccine.2008.05.064; Bosch FX, 2002, J CLIN PATHOL, V55, P244; Brown DR, 2009, J INFECT DIS, V199, P926, DOI 10.1086-597307; Bulk S, 2006, BRIT J CANCER, V94, P171, DOI 10.1038-sj.bjc.6602915; Bulk S, 2007, BRIT J CANCER, V96, P1234, DOI 10.1038-sj.bjc.6603693; Bulk S, 2005, INT J CANCER, V113, P1005, DOI 10.1002-ijc.20678; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128-CMR.16.1.1-17.2003; Burger RA, 1996, J NATL CANCER I, V88, P1361, DOI 10.1093-jnci-88.19.1361; Castellsague X, 2006, J NATL CANCER I, V98, P303, DOI 10.1093-jnci-djj067; Centers for Disease Control and Prevention (CDC), 2010, MMWR-MORBID MORTAL W, V59, P626; Chen RJ, 1999, GYNECOL ONCOL, V73, P184, DOI 10.1006-gyno.1999.5364; Clifford G, 2008, INT J CANCER, V122, P1684, DOI 10.1002-ijc.23282; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016-j.vaccine.2008.06.019; DAVIS JR, 1975, OBSTET GYNECOL, V45, P79; Davy MLJ, 2003, OBSTET GYNECOL, V101, P38, DOI 10.1016-S0029-7844(02)02275-5; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001-jama.294.17.2173; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016-S1473-3099(07)70158-5; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016-S1470-2045(10)70230-8; DEVESA SS, 1984, OBSTET GYNECOL, V63, P605; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016-j.virol.2004.03.033; De Vuyst H, 2008, INT J CANCER, V122, P244, DOI 10.1002-ijc.23045; Dillner J, 2008, BRIT MED J, V337, DOI 10.1136-bmj.a1754; EIFEL PJ, 1995, GYNECOL ONCOL, V59, P38, DOI 10.1006-gyno.1995.1265; EIFEL PJ, 1990, CANCER, V65, P2507, DOI 10.1002-1097-0142(19900601)65:112507::AID-CNCR28206511203.0.CO;2-9; El-Mansi MT, 2006, INT J GYNECOL CANCER, V16, P1025; *EMA, 2010, GARD SUMM PROD CHAR; *EMA, 2011, CERV SUMM PROD CHAR; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038-sj.onc.1206528; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002-ijc.25516; Franco EL, 2008, VACCINE, V26, pA16, DOI 10.1016-j.vaccine.2007.11.069; Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371-journal.pmed.0050132; GALLUP DG, 1977, OBSTET GYNECOL, V49, P596; Gien LT, 2010, GYNECOL ONCOL, V116, P140, DOI 10.1016-j.ygyno.2009.09.040; *GLOBOCAN, 2002, GLOBOCAN 2002 CANC I; Goldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016-j.vaccine.2007.05.058; Gunnell AS, 2007, CANCER EPIDEM BIOMAR, V16, P2641, DOI 10.1158-1055-9965.EPI-07-0278; Han CP, 2009, INT J GYNECOL PATHOL, V28, P489, DOI 10.1097-PGP.0b013e31819e8ab4; Hayes MMM, 1997, CYTOPATHOLOGY, V8, P397, DOI 10.1111-j.1365-2303.1997.tb00570.x; HEPLER TK, 1952, AM J OBSTET GYNECOL, V63, P800; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054-bjoc.2001.1779; Hirschowitz L, 2007, DIAGN PATHOL, V2, DOI 10.1186-1746-1596-2-40; HOPKINS MP, 1991, OBSTET GYNECOL, V77, P912; HOROWITZ IR, 1988, GYNECOL ONCOL, V31, P25, DOI 10.1016-0090-8258(88)90265-X; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016-j.ygyno.2003.11.035; Insinga RP, 2008, CANCER EPIDEM BIOMAR, V17, P1611, DOI 10.1158-1055-9965.EPI-07-2922; *INT AG RES CANC, 2005, IARC HDB CANC PREV, V10, P201; Irie T, 2000, EUR J SURG ONCOL, V26, P464, DOI 10.1053-ejso.1999.0923; JAWORSKI RC, 1990, SEMIN DIAGN PATHOL, V7, P190; Khan MJ, 2005, J NATL CANCER I, V97, P1072, DOI 10.1093-jnci-dji187; KIM MJ, 2010, IPVC 2010 MONTR CAN; Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016-S1470-2045(09)70156-1; Kitchener HC, 2006, BRIT J CANCER, V95, P56, DOI 10.1038-sj.bjc.6603210; Kjaer SK, 2009, CANCER PREV RES, V2, P868, DOI 10.1158-1940-6207.CAPR-09-0031; KLEINE W, 1989, GYNECOL ONCOL, V35, P145, DOI 10.1016-0090-8258(89)90032-2; Kong CS, 2010, AM J SURG PATHOL, V34, P915, DOI 10.1097-PAS.0b013e3181e3291e; Lacey JV, 2003, CANCER-AM CANCER SOC, V98, P814, DOI 10.1002-cncr.11567; Lacey JV, 2001, CANCER CAUSE CONTROL, V12, P153, DOI 10.1023-A:1008918310055; Lai CH, 2007, INT J CANCER, V120, P1999, DOI 10.1002-ijc.22538; Lee KB, 2006, INT J GYNECOL CANCER, V16, P1569, DOI 10.1111-j.1525-1438.2006.00628.x; Lee KR, 2003, INT J GYNECOL PATHOL, V22, P22, DOI 10.1097-01.PGP.0000040034.16722.5F; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002-ijc.25396; Liu SL, 2001, CAN MED ASSOC J, V164, P1151; Liu SS, 2008, TUMOR BIOL, V29, P105, DOI 10.1159-000135690; Marchiole P, 2007, GYNECOL ONCOL, V106, P132, DOI 10.1016-j.ygyno.2007.03.009; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; Mayor Susan, 2003, BMJ, V327, P948, DOI 10.1136-bmj.327.7421.948-d; Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056-NEJMoa071430; McCluggage WG, 2002, INT J GYNECOL PATHOL, V21, P11, DOI 10.1097-00004347-200201000-00003; McKeage K, 2011, DRUGS, V71, P465, DOI 10.2165-11206820-000000000-00000; Mesher D, 2010, BRIT J CANCER, V102, P1405, DOI 10.1038-sj.bjc.6605619; MIKUTA JJ, 1969, OBSTET GYNECOL, V33, P753; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002-ijc.20244; Munoz N, 2010, J NATL CANCER I, V102, P325, DOI 10.1093-jnci-djp534; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016-S0140-6736(02)08151-5; Nakanishi T, 2000, GYNECOL ONCOL, V79, P289, DOI 10.1006-gyno.2000.5935; Noller KL, 2003, OBSTET GYNECOL, V102, P259, DOI 10.1016-S0029-7844(03)00565-9; Ostor A, 1997, OBSTET GYNECOL, V89, P88, DOI 10.1016-S0029-7844(96)00386-9; Paavonen J, 2009, Lancet, V374, P301, DOI 10.1016-S0140-6736(09)61248-4; PAAVONEN J, 2010, IPVC 2010 MONTR CAN; Pak SC, 2007, AUST NZ J OBSTET GYN, V47, P504, DOI 10.1111-j.1479-828X.2007.00788.x; Parkin DM, 2006, VACCINE S3, V24, pS11, DOI 10.1016-j.vaccine.2006.05.111; Peedicayil A, 2006, INT J GYNECOL CANCER, V16, P1591, DOI 10.1111-j.1525-1438.2006.00631.x; Peters WA, 2000, J CLIN ONCOL, V18, P1606; PIMENTA J, 2009, 19 FIGO WORLD C; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016-S0002-9440(10)64619-6; Quinn M, 2006, INT J GYNECOL OBSTET, V95, pS43, DOI 10.1016-S0020-7292(06)60030-1; Richart RM, 1967, CLIN OBSTET GYNECOL, V10, P748, DOI 10.1097-00003081-196712000-00002; ROMANOWSKI B, 2010, IPVC 2010 MONTR CAN; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016-S1470-2045(09)70360-2; ROTELIMARTINS CM, 2010, ESPID 2010 NIC FRANC; Sasieni P, 2009, INT J CANCER, V125, P525, DOI 10.1002-ijc.24410; Sasieni P, 2009, BRIT MED J, V339, DOI 10.1136-bmj.b2968; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016-j.virol.2005.04.002; Schiffman M, 2003, J NATL CANC I MONOGR, V31, P14; SCHIFFMAN M, 2010, IPVC 2010 MONTR CAN; SCHORR M, 2009, LIQUID BASED PAP TES; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906; Shimada M, 2006, GYNECOL ONCOL, V101, P234, DOI 10.1016-j.ygyno.2005.10.004; SHINGLETON HM, 1995, CANCER, V76, P1948, DOI 10.1002-1097-0142(19951115)76:10+1948::AID-CNCR28207613113.0.CO;2-T; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006-gyno.2000.5826; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002-ijc.22527; Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016-S0140-6736(03)12949-2; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001-jama.287.16.2114; STOLER MH, 1991, AM J SURG PATHOL, V15, P28, DOI 10.1097-00000478-199101000-00003; TABATA M, 1987, GYNECOL ONCOL, V28, P255, DOI 10.1016-0090-8258(87)90170-3; TJALMA W, 2010, IPVC 2010 MONTR CAN; TJALMA W, 2010, IGCS 2010 PRAG CZECH; Vinh-Hung V, 2007, BMC CANCER, V7, DOI 10.1186-1471-2407-7-164; Vinokurova S, 2008, CANCER RES, V68, P307, DOI 10.1158-0008-5472.CAN-07-2754; Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002-(SICI)1097-0215(20000501)86:3429::AID-IJC203.0.CO;2-D; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002-(SICI)1097-0215(19980209)75:4536::AID-IJC83.0.CO;2-U; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002-(SICI)1096-9896(199909)189:112::AID-PATH4313.0.CO;2-F; Wheeler CM, 2009, J NATL CANCER I, V101, P475, DOI 10.1093-jnci-djn510; *WHO, 2010, WHO ICO INF CTR HUM; Wiley DJ, 2002, CLIN INFECT DIS, V35, pS210, DOI 10.1086-342109; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P314, DOI 10.1097-01.PGP.0000035801.90350.90; 1997, CYTOPATHOLOGY, V1997, P818181
Detailed gene and allele content analysis of three homozygous KIR haplotypes
No full textThe killer immunoglobulin-like receptors are a highly polymorphic family of receptors encoded by 15 genes clustered on 19q13.4. Because of the complexity of the genetic analysis of the KIR cluster, much of the data regarding KIR sequences and alleles has been generated by cDNA typing and partial sequencing. Here we report the genomic sequencing of the KIR genes in individuals with three different haplotypes homozygous by descent. We provide a detailed analysis of their haplotypes and identify new alleles for KIR3DL3 and KIR2DL1. The primers we describe will be a valuable tool for studying the involvement of the KIR genes in various human diseases. © 2006 R. Slim.Carrington M, 2003, KIR GENE CLUSTER; Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1081-jem.20042158; Gedil MA, 2005, TISSUE ANTIGENS, V65, P402, DOI 10.1111-j.1399-0039.2005.00380.x; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084-jem.20041214; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034-j.1600-065X.2002.19004.x; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126-science.1097670; Kinoshita T, 2005, J BIOL CHEM, V280, P21720, DOI 10.1074-jbc.M410057200; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146-annurev.immunol.16.1.359; Luszczek W, 2004, HUM IMMUNOL, V65, P758, DOI 10.1016-j.humimm.2004.05.008; Martin AM, 2004, GENE, V335, P121, DOI 10.1016-j.gene.2004.03.018; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038-ng934; Martin MP, 2003, J IMMUNOL, V171, P2192; Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016-j.coi.2004.07.010; Murdoch S, 2006, NAT GENET, V38, P300, DOI 10.1038-ng1740; Rajalingam R, 2004, J IMMUNOL, V172, P356; SEOUD M, 1995, OBSTET GYNECOL, V86, P692, DOI 10.1016-0029-7844(95)00033-N; Trundley AE, 2006, IMMUNOGENETICS, V57, P904, DOI 10.1007-s00251-005-0060-7; Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016-S1074-7613(00)80394-5; Uhrberg M, 2005, EUR J IMMUNOL, V35, P10, DOI 10.1002-eji.200425743; Varla-Leftherioti M, 2003, AM J REPROD IMMUNOL, V49, P183, DOI 10.1034-j.1600-0897.2003.00018.x; Yen JH, 2001, J EXP MED, V193, P1159, DOI 10.1084-jem.193.10.115910111
Inguinal ovary after controlled ovarian hyperstimulation-infrequent, infrequently recognized, or observer variation?
No full text[No abstract available]BAZI T, 2006, FERTIL STERIL, V85, pE5; Hinckley MD, 2003, FERTIL STERIL, V80, P445, DOI 10.1016-S0015-0282(03)00668-X; Idil M, 2006, FERTIL STERIL, V85, DOI 10.1016-j.fertnstert.2005.11.066; Mayer V, 1941, ARCH SURG-CHICAGO, V43, P397; Ombelet W, 2003, HUM REPROD, V18, P858, DOI 10.1093-humrep-deg1911
Burden of human papillomavirus infections and related diseases in the extended middle east and North Africa Region
No full textIn this chapter, we present the available information on the burden of human papillomavirus (HPV)-related cancers (cancers of the cervix, anogenital cancers, and cancers of the oral cavity and pharynx), as well as available data on the prevalence and distribution of HPV types in women with and without cervical cancer, for the countries of the Extended Middle East and North Africa region (EMENA). The EMENA region is characterized by societies that share similar cultures and religions and that are considered to have a more conservative sexual behaviour compared to Western societies. The incidence of cervical cancer is estimated to be relatively low, although it is difficult to assess precisely because systematic and national cancer registries are lacking in many countries of the EMENA region. In these countries, nationwide programs of cervical cancer screening do not exist or are based on a limited opportunistic cytology-based screening, which often lacks quality assurance. The incidence of anogenital cancers other than cervix is very low. The incidence of cancers of the oral cavity and pharynx is relatively high in some countries, particularly in Pakistan. Relatively low levels of HPV prevalence have been observed in the several surveys conducted in the EMENA region, although only few young women were included in these studies. Possible changes in lifestyle and sexual behaviour in younger generations might, however, change this scenario. Thus, improving the information on the burden of HPV-related cancers and on the HPV prevalence in the general population is essential to develop a comprehensive intervention policy for future management of cervical cancer in this area.This article forms part of a regional report entitled . Comprehensive Control of HPV Infections and Related Diseases in the Extended Middle East and North Africa Region Vaccine Volume 31, Supplement 6, 2013. Updates of the progress in the field are presented in a separate monograph entitled . Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. © 2013 Elsevier Ltd.Aziz MTA, 2006, MED SCI MONITOR, V12, pMT43; Abd El-Azim S, 2011, CLIN LAB, V57, P363; Abdullah LS, 2007, ANN SAUDI MED, V27, P268; Ahmed MI, 2001, CLIN BIOCHEM, V34, P491, DOI 10.1016-S0009-9120(01)00243-0; Al-Awadhi R, 2011, J MED VIROL, V83, P453, DOI 10.1002-jmv.21981; Alhamany Z, 2010, J INFECT DEV COUNTR, V4, P732; Al Jaroudi D, 2010, ANN SAUDI MED, V30, P397, DOI [10.4103-0256-4947.68550, 10.4103-0236-4947.68330]; Allameh T, 2011, ARCH GYNECOL OBSTET, V284, P1509, DOI 10.1007-s00404-011-1863-4; Altun Z, 2011, TURK KLIN TIP BILIM, V31, P307, DOI 10.5336-medsci.2009-16463; Amrani M, 2003, J CLIN VIROL, V27, P286, DOI 10.1016-S1386-6532(02)00227-5; Balaha MH, 2011, J CYTOL, V28, P173, DOI 10.4103-0970-9371.86343; Bayram A, 2011, J MED VIROL, V83, P1997, DOI 10.1002-jmv.22218; Ben Aissa R, 2002, ONFP TUNIS MED, V80, P203; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086-657321; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002-(SICI)1097-0215(19980209)75:4546::AID-IJC93.0.CO;2-T; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016-S0140-6736(05)67069-9; Curado MP, 2007, IARC SCI PUBLICATION, VIX; de Martel Catherine, 2012, Lancet Oncol, V13, P607, DOI 10.1016-S1470-2045(12)70137-7; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016-S1470-2045(10)70230-8; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002-ijc.24116; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056-NEJMoa065497; Dursun P, 2009, BMC INFECT DIS, V9, DOI 10.1186-1471-2334-9-191; el-All Howayda S Abd, 2007, Infect Agent Cancer, V2, P12; El-Kak F, 2013, VACCINE, V31, pG45, DOI 10.1016-j.vaccine.2012.10.120; El Khair MM, 2010, MED ONCOL, V27, P861, DOI 10.1007-s12032-009-9297-6; Eren F, 2010, INT J GYNECOL OBSTET, V109, P235, DOI 10.1016-j.ijgo.2010.01.007; Esmaeili M, 2008, GYNECOL OBSTET INVES, V66, P68, DOI 10.1159-000134917; Ferlay J, 2010, IARC CANCERBASE; Franceschi S, 2005, BRIT J CANCER, V92, P601, DOI 10.1038-sj.bjc.6602348; Ghaffari Saeed Reza, 2006, Asian Pac J Cancer Prev, V7, P529; Ghazal-Aswad S, 2006, ACTA CYTOL, V50, P41, DOI 10.1159-000325893; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002-ijc.27485; Hajjaj AA, 2006, SAUDI MED J, V27, P487; Hamkar R, 2002, East Mediterr Health J, V8, P805; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002-ijc.20600; Hammouda D, 2011, INT J CANCER, V128, P2224, DOI 10.1002-ijc.25539; Hassen E, 2003, INFECTION, V31, P143, DOI 10.1007-s15010-003-3112-7; Inal MM, 2007, INT J GYNECOL CANCER, V17, P1266, DOI 10.1111-j.1525-1438.2007.00944.x; Kapila K, 2006, MED PRIN PRACT, V15, P253, DOI 10.1159-000092986; Karabulut A, 2010, INT J GYNECOL OBSTET, V110, P40, DOI 10.1016-j.ijgo.2010.02.011; Karam WG, 2011, J BIOL REG HOMEOS AG, V25, P453; Karam WG, 2005, LEBAN MED J, V53, P132; Kasap B, 2011, EUR J OBSTET GYN R B, V159, P168, DOI 10.1016-j.ejogrb.2011.06.021; Keita N, 2009, BRIT J CANCER, V101, P202, DOI 10.1038-sj.bjc.6605140; Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016-j.ijid.2006.06.007; Khodakarami N, 2012, INT J CANCER, V131, pE156, DOI 10.1002-ijc.26488; KrennHrubec K, 2011, J MED VIROL, V83, P651, DOI 10.1002-jmv.22011; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002-ijc.25396; Luthra UK, 2002, ACTA CYTOL, V46, P303, DOI 10.1159-000326726; Missaoui N, 2010, ASIAN PAC J CANCER P, V11, P235; Missaoui N, 2010, ANN BIOL CLIN-PARIS, V68, P297, DOI 10.1684-abc.2010.0431; Missaoui N, 2010, ASIAN PAC J CANCER P, V11, P777; Mortazavi S, 2002, ASIAN PAC J CANCER P, V3, P69; Mroueh AM, 2002, EUR J GYNAECOL ONCOL, V23, P429; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Nokiani FA, 2008, ASIAN PAC J CANCER P, V9, P107; Ozcan ES, 2011, J OBSTET GYNAECOL, V31, P656, DOI 10.3109-01443615.2011.597460; Ozgul N, 2008, J OBSTET GYNAECOL RE, V34, P865, DOI 10.1111-j.1447-0756.2008.00795.x; Ozturk Sual, 2004, Mikrobiyoloji Bulteni, V38, P223; Plummer M, 2012, INT J CANCER, V130, P2638, DOI 10.1002-ijc.26250; Rasul S, 1991, Asia Oceania J Obstet Gynaecol, V17, P1; Raza SA, 2010, BRIT J CANCER, V102, P1657, DOI 10.1038-sj.bjc.6605664; Safaei A, 2010, INDIAN J PATHOL MICR, V53, P681, DOI 10.4103-0377-4929.72030; Sancho-Garnier H, 2013, VACCINE, V31, pG51, DOI 10.1016-j.vaccine.2012.06.046; Seoud M, 2012, J LOW GENIT TRACT DI, V16, P106, DOI 10.1097-LGT.0b013e31823a0108; Shahsiah R, 2011, PATHOL RES PRACT, V207, P754, DOI 10.1016-j.prp.2011.09.011; Soerjomataram I, 2012, BMC MED RES METHODOL, V12, DOI 10.1186-1471-2288-12-125; Sughayer MA, 2010, INT J GYNECOL OBSTET, V108, P74, DOI 10.1016-j.ijgo.2009.08.025; Kara F, 2009, INT J GYNECOL OBSTET, V106, P206, DOI 10.1016-j.ijgo.2009.04.003; Usubutun A, 2009, INT J GYNECOL PATHOL, V28, P541, DOI 10.1097-PGP.0b013e3181aaba0d; Wasti S, 2004, ANN SAUDI MED, V24, P189; Yalti S, 2005, INT J GYNECOL CANCER, V15, P292, DOI 10.1111-j.1525-1438.2005.15218.x; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307-2939232; Zandi K, 2010, VIROL J, V7, DOI 10.1186-1743-422X-7-65; Zavarei M, 2012, IRAN J PUBLIC HEALTH, V37, P10135
Dr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
"Reflections on the subject of Emigration from Europe with a view to Settlement in the United States" By M. Carey.
No full text"Reflections on the subject of Emigration from Europe with a view to Settlement in the United States: containing bried sketches of the moral and political character of those states.
By M. Carey, member of the American philosophical, and of the American Antiquarian Society, and author of The Olive Branch, Cindiciae Hibernicae, essays on banking, on political economy, and on internal improvement.
To which are now added the English editor's comments on the subject; together with Important Advice to Emigrants, and Cautions Against Impositions Practiced in the Outports
- …
